Cargando…
Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine
Whether telbivudine (LdT) treatment to pregnant women with hepatitis B surface antigen (HBsAg) affects infant immune response to hepatitis B vaccine (HepB) has not been investigated. A total of 127 HBsAg positive mothers and their neonates were enrolled and followed up at 11–13 months. Mothers took...
Autores principales: | Li, Yandi, Chen, Wenxin, Jin, Cong, Wang, Ting, Yao, Tian, Feng, Shuying, Wang, Bo, Feng, Yongliang, Wang, Suping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993090/ https://www.ncbi.nlm.nih.gov/pubmed/35296227 http://dx.doi.org/10.1080/21645515.2022.2029259 |
Ejemplares similares
-
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
por: Zhang, Hua, et al.
Publicado: (2014) -
Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction
por: Wang, Xiaoli, et al.
Publicado: (2023) -
Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study
por: Lin, Kuan-Yin, et al.
Publicado: (2023) -
Role of S protein transmembrane domain mutations in the development of occult hepatitis B virus infection
por: Jiang, Xinyi, et al.
Publicado: (2022) -
Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study
por: Tang, Zi-Min, et al.
Publicado: (2022)